Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combination radiation and αPD-L1 enhance tumor control by stimulating CD8+ PD-1+ TCF-1+ T cells in the tumor-draining lymph node.

Nature communications·2025
Same author

Muc16CD is a novel CAR T cell target antigen for the treatment of pancreatic cancer.

Molecular therapy. Oncology·2024
Same author

TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models.

Molecular therapy. Oncology·2024
Same author

Stable Dual miR-143 and miR-506 Upregulation Inhibits Proliferation and Cell Cycle Progression.

International journal of molecular sciences·2024
Same author

Radiation and anti-PD-L1 synergize by stimulating a stem-like T cell population in the tumor-draining lymph node.

Research square·2024
Same author

Engineering Improved CAR T Cell Products with A Multi-Cytokine Particle Platform for Hematologic and Solid Tumors.

Advanced healthcare materials·2024

Related Experiment Video

Updated: Nov 12, 2025

Direct Protein Delivery to Mammalian Cells Using Cell-permeable Cys2-His2 Zinc-finger Domains
11:24

Direct Protein Delivery to Mammalian Cells Using Cell-permeable Cys2-His2 Zinc-finger Domains

Published on: March 25, 2015

10.2K

Using Adoptive Cellular Therapy for Localized Protein Secretion.

Alysa N Evans1, Heather K Lin2, A K M Nawshad Hossian1

  • 1From the Department of Hematology and Medical Oncology.

Cancer Journal (Sudbury, Mass.)
|March 22, 2021
PubMed
Summary

Chimeric antigen receptor (CAR) T cells can be engineered to secrete proteins, enhancing their ability to fight tumors. This approach aims to improve treatment effectiveness and durability by modifying the tumor microenvironment.

More Related Videos

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

18.7K
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.6K

Related Experiment Videos

Last Updated: Nov 12, 2025

Direct Protein Delivery to Mammalian Cells Using Cell-permeable Cys2-His2 Zinc-finger Domains
11:24

Direct Protein Delivery to Mammalian Cells Using Cell-permeable Cys2-His2 Zinc-finger Domains

Published on: March 25, 2015

10.2K
Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

18.7K
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.6K

Area of Science:

  • Immunology
  • Cancer Biology
  • Biotechnology

Background:

  • Chimeric antigen receptor (CAR) T cell therapy shows promise in redirecting T cell cytotoxicity against tumors.
  • However, CAR T cell efficacy can be limited by the complex tumor microenvironment (TME).
  • Optimizing CAR T cell function requires strategies beyond simple cytotoxicity redirection.

Purpose of the Study:

  • To investigate the potential of co-modifying CAR T cells to secrete therapeutic proteins.
  • To enhance CAR T cell function and overcome suppressive signals within the TME.
  • To improve both the initial response and durability of CAR T cell therapy.

Main Methods:

  • Engineering CAR T cells to secrete various classes of proteins (agonistic and antagonistic).
  • Evaluating the impact of secreted proteins on CAR T cell function in preclinical models.
  • Assessing the ability of CAR T cells to locally deliver therapeutic molecules to the TME.

Main Results:

  • Co-modification strategies show potential to optimize CAR T cell antitumor activity.
  • Secreted proteins can alter the TME milieu and overcome suppressive signals.
  • Local delivery of therapeutic molecules avoids systemic distribution, potentially reducing side effects.

Conclusions:

  • Engineered CAR T cells secreting therapeutic proteins represent a promising strategy to enhance cancer immunotherapy.
  • This approach has demonstrated efficacy in preclinical settings and is advancing to clinical trials.
  • Further research and clinical evaluation are crucial to establish the full therapeutic potential.